Indications for: NEXLIZET
An adjunct to diet and maximally tolerated statin therapy, in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use:
The effect on cardiovascular morbidity and mortality has not been determined.
Swallow whole. 180mg/10mg once daily. After initiation, assess lipid levels within 8–12 weeks. Concomitant bile acid sequestrants: give Nexlizet either ≥2hrs before or ≥4hrs after.
Hyperuricemia. Assess serum uric acid as clinically indicated. History of gout. Increased risk for tendon rupture/injury (esp. >60yrs, in those taking corticosteroid or fluoroquinolone drugs, renal failure, previous tendon disorders); consider discontinuing if joint pain, swelling, or inflammation develop. History of tendon disorders/rupture: consider alternative therapy. Elderly. Moderate or severe hepatic (Child-Pugh B or C): not recommended. Severe renal impairment (eGFR <30mL/min/1.73 m2). ESRD on dialysis. Pregnancy, nursing mothers: not recommended.
Adenosine triphosphate-citrate lyase (ACL) inhibitor + cholesterol absorption inhibitor.
Avoid concomitant simvastatin >20mg or pravastatin >40mg. Concomitant cyclosporine increases ezetimibe and cyclosporine levels; monitor. Concomitant use with fibrates (except fenofibrate): not recommended. Concomitant use with fenofibrate: consider alternative therapy if cholelithiasis is suspected. Antagonized by cholestyramine (see Adult dose).
Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, arthralgia, sinusitis, fatigue, influenza; BPH, atrial fibrillation, hypersensitivity reactions (ezetimibe).
Generic Drug Availability: